Page last updated: 2024-12-09

fumonisin b2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fumonisin B2: produced by Fusarium moniliforme MRC 826; structure given in first source; has cancer-promoting ability [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fumonisin B2 : A fumonisin that is (2S,3S,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,14,15-triol in which the hydroxy groups at positions 14 and 15 have each been esterified by condensation with the 1-carboxy group of 3-carboxyglutaric acid (giving a 3-carboxyglutarate ester group with R configuration in each case). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2733489
CHEMBL ID1700939
CHEBI ID38225
SCHEMBL ID622287
MeSH IDM0159546

Synonyms (30)

Synonym
(2r,2'r)-2,2'-{[(5r,6r,7s,9s,16r,18s,19s)-19-amino-16,18-dihydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}dibutanedioic acid
CHEBI:38225 ,
116355-84-1
fumonisin b2
1,2,3-propanetricarboxylic acid, 1,1'-(1-(12-amino-9,11-dihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl) ester
ccris 4434
1,2,3-propanetricarboxylic acid, 1,1'-(1-(2-amino-9,11-dihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl) ester
NCGC00163557-01
fumonisin b2, fusarium moniliforme
LMSP01080023
C19242
CHEMBL1700939
ux4wht4mkb ,
fumonisin-b2
unii-ux4wht4mkb
CCG-208209
SCHEMBL622287
SR-05000002349-2
sr-05000002349
1,2,3-propanetricarboxylic acid, 1,1'-[(1s,2r)-1-[(2s,9r,11s,12s)-12-amino-9,11-dihydroxy-2-methyltridecyl]-2-[(1r)-1-methylpentyl]-1,2-ethanediyl] ester, (2r,2'r)-
(2r)-2-[2-[(5r,6r,7s,9s,16r,18s,19s)-19-amino-6-[(3r)-3,4-dicarboxybutanoyl]oxy-16,18-dihydroxy-5,9-dimethylicosan-7-yl]oxy-2-oxoethyl]butanedioic acid
DTXSID80891857
Q5508613
HY-N6723
CS-0099766
1,2,3-propanetricarboxylic acid, 1,1'-[1-(12-amino-9,11-dihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl] ester, [2s-[1[1r*(s*),2s*(s*),2(s*)],2r*,9s*,11r*,12r*]]-; fumonisin b2
BF162728
(2r,2'r)-2,2'-((((5r,6r,7s,9s,16r,18s,19s)-19-amino-16,18-dihydroxy-5,9-dimethylicosane-6,7-diyl)bis(oxy))bis(2-oxoethane-2,1-diyl))disuccinic acid
1,2,3-propanetricarboxylic acid, 1,1'-[1-(12-amino-9,11-dihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl] ester, [2s-[1[1r*(s*),2s*(s*),2(s*)],2r*,9s*,11r*,12r*]]-
AKOS040741772

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Fumonisins B1 and B2, produced by Fusarium moniliforme Sheldon induce toxic hepatitis and hepatomas in rats and leukoencephalomalacia in horses."( Toxicity of the mycotoxins fumonisins B1 and B2 and Alternaria alternata f. sp. lycopersici toxin (AAL) in cultured mammalian cells.
Abbas, HK; Mirocha, CJ; Shier, WT, 1991
)
0.28
" Fumonisins B1 and B2 were extracted from the CM by water, but not chloroform/methanol, and were present in the toxic diets at concentrations of 93-139 and 82-147 ppm, respectively."( Comparative studies of hepatotoxicity and fumonisin B1 and B2 content of water and chloroform/methanol extracts of Fusarium moniliforme strain MRC 826 culture material.
Bacon, CW; Norred, WP; Plattner, RD; Voss, KA, 1990
)
0.28
" Of the substances tested, fumonisin B(1) emerged to be the most toxic whereas its N-carboxymethyl analogue was 100-fold less effective."( Toxicity assessment of fumonisins using the brine shrimp (Artemia salina) bioassay.
Hartl, M; Humpf, HU, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
"The ability of lactic acid bacteria (LAB) to bind fumonisins B1 and B2 (FB1, FB2) in fermented foods and feeds and in the gastrointestinal tract could contribute to decrease their bioavailability and toxic effects on farm animals and humans."( Cell wall component and mycotoxin moieties involved in the binding of fumonisin B1 and B2 by lactic acid bacteria.
Aboab, B; Boudra, H; Lemaire, M; Morgavi, DP; Niderkorn, V, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
"To examine the effects of acute exposure to fumonisin-containing culture material (FCCM), 15 crossbred wether lambs were dosed intraruminally with FCCM containing 0 (CONTROL, n = 3), 11."( Acute hepatic and renal toxicity in lambs dosed with fumonisin-containing culture material.
Edrington, TS; Elissalde, MH; Harvey, RB; Kamps-Holtzapple, CA; Kubena, LF; Rottinghaus, GE, 1995
)
0.29
" In a short preliminary study, they have been applied to the determination of the fate of FB2 dosed to rats by gavage."( Liquid chromatographic determination of the mycotoxin fumonisin B2 in physiological samples.
Shephard, GS; Sydenham, EW; Thiel, PG, 1995
)
0.54
" We examined the temporal and dose-response features of FB1 toxicosis in male weanling crossbred pigs fed nutritionally balanced diets, containing corn screenings naturally contaminated with fumonisins, for 14 days."( Temporal and dose-response features in swine fed corn screenings contaminated with fumonisin mycotoxins.
Beasley, VR; Hall, WF; Harlin, KS; Haschek, WM; Motelin, GK; Ness, DK; Schaeffer, DJ, 1994
)
0.29
" A transmission study using four cows dosed with pure FB1 either orally (1."( Determination of fumonisins in milk.
Delgado, T; Miller, JD; Prelusky, DB; Scott, PM; Trenholm, HL, 1994
)
0.29
" The respective aminopolyols exhibited a higher cytotoxicity than did the parent compounds, while tricarballylic acid (TCA) exhibited no dose-response effect despite the fact that it had a higher background cytotoxicity compared with the control."( Structure-activity relationships of fumonisins in short-term carcinogenesis and cytotoxicity assays.
Cawood, ME; Gelderblom, WC; Marasas, WF; Snyman, SD; Vleggaar, R, 1993
)
0.29
"The mycotoxin fumonisin B2 (FB2), which can be present at significant levels in maize infected with the fungus Fusarium moniliforme, was dosed both iv and by gavage to vervet monkeys."( Elimination and excretion of a single dose of the mycotoxin fumonisin B2 in a non-human primate.
Shephard, GS; Snijman, PW,
)
0.73
" The most sensitive adverse response in rats, nephrotoxic lesions, was used for the dose-response analysis."( A quantitative risk assessment for fumonisins B1 and B2 in US corn.
Bolger, M; Carrington, C; Humphreys, SH, 2001
)
0.31
" This study characterized the conversion of HFB1 and HFB2 by ceramide synthase to their respective N-acylated metabolites using rat liver microsomes and palmitoyl-CoA or nervonoyl-CoA as cosubstrates, and examined animals that had been dosed with hydrolyzed fumonisins to ascertain if acylation occurs in vivo."( Hydrolyzed fumonisins HFB1 and HFB2 are acylated in vitro and in vivo by ceramide synthase to form cytotoxic N-acyl-metabolites.
Allegood, JC; Humpf, HU; Merrill, AH; Seiferlein, M; Sullards, MC; Voss, KA; Wang, E, 2007
)
0.34
" Only a small amount of FB(2) was detected in plasma after oral dosing of 10 mg of FB(2)/kg of BW."( Toxicokinetics of fumonisin B2 in ducks and turkeys.
Benlashehr, I; Guerre, P; Jouglar, JY; Repussard, C; Tardieu, D, 2011
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Aspergillus metaboliteAny fungal metabolite produced during a metabolic reaction in the mould, Aspergillus.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
fumonisinA family of toxins produced by several species of Fusarium moulds which occur mainly in maize.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
diolA compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols.
diesterA diester is a compound containing two ester groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency44.66840.016525.307841.3999AID602332
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (280)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.71)18.7374
1990's107 (38.21)18.2507
2000's82 (29.29)29.6817
2010's80 (28.57)24.3611
2020's9 (3.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.75 (24.57)
Research Supply Index5.77 (2.92)
Research Growth Index6.87 (4.65)
Search Engine Demand Index37.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.63%)5.53%
Reviews14 (4.42%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other301 (94.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]